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SUMMARY. There has been no clear evidence demonstrating whether DNA hypermethylation can affect the
prognosis of esophageal cancer. We collected tissue from 50 cases of squamous cell carcinoma of the esophagus and
tested them for DNA hypermethylation using methylation-specific polymerase chain reaction. CpG island hyper-
methylations were observed in 10% for p16, 34% for RARbP2, 46% for adenomatosis polyposis coli (APC), 14%
for RASSF1A, 84% for FHIT, and 8% for hMLH1. APC promoter hypermethylation was frequently found in
patients without lymph node metastasis compared with those with lymph node metastasis (62.5% : 30.8%,
P = 0.025). The number of metastatic lymph nodes were lower in patients with APC promoter hypermethylation
(0.87  0.30 : 3.07  0.72, P = 0.008). Excluding operative mortalities and incomplete resections, 42 patients
were analyzed for long-term outcome. During the mean follow-up period of 35 months, 17 developed recurrence and
14 died of cancer. Ten patients died of other causes. In univariable analysis, unmethylation of APC (P = 0.0015)
and FHIT (P = 0.0044), as well as presence of lymph node metastasis (P = 0.0038), were risk factors for recur-
rence. In multivariable analysis, lymph nodes metastasis (P = 0.050) and unmethylation of APC promoter
(P = 0.023) remained as significant risk factors. In conclusion, promoter hypermethylation of the APC gene is
related to a lower number of metastatic lymph nodes and to superior prognosis in terms of recurrence, which
suggests it might be involved in the process of lymph node metastasis in esophageal cancer.
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INTRODUCTION
Epigenetic changes of DNA have been recently high-
lighted and DNA methylation study is one of the
best studied subjects in the field of cancer epigenetic.
Various researches have been performed to identify
the clinical significance of DNA methylation patterns
in malignant tumors. However, only a limited
number of reports have been published for the aber-
rant promoter hypermethylation in esophageal squa-
mous cell carcinoma. Although the incidence of
esophageal cancer is not very high, survival rates
remain low despite the recent improvement of treat-
ment strategies. However, none of the molecular
markers have been addressed to predict its long-term
outcome of esophageal cancer.
We examined whether aberrant promoter hyperm-
ethylation of various tumor suppressor genes could
be used to predict clinical outcomes of patients with
esophageal squamous cell carcinoma after surgical
resection, focusing on lymph node metastasis. We
also tried to investigate a possible mechanism in




Among the 161 patients who underwent surgical
resection for esophageal carcinoma between October
2000 and May 2005 at Seoul National University
Hospital, we selected 50 patients whose histological
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cell type was squamous cell carcinoma and whose
frozen specimens were available from our Thoracic
Cancer Tissue Bank. Informed consents for tissue
collection and gene analyses for research purposes
were obtained from individual patients preopera-
tively according to the policy of the Thoracic Cancer
Tissue Bank, Cancer Research Institute, Seoul
National University. Recommendations from the
Declaration of Helsinki for Biomedical Research
involving Human Subjects were also followed. The
study protocol, as well as ethical issues, was reviewed
by the Seoul National University Hospital IRB
(C-0701-004-193).
Forty-seven patients were male and three were
female (mean age, 64 years; range, 49–78 years).
Esophagectomy and subsequent esophagogastros-
tomy were performed either at the thoracic or at the
cervical level, depending on the location of the
tumor. Radical mediastinal and perigastric lymph
node dissection were performed in all patients. Two
patients had a history of lung cancer, which had
been resected curatively, and two patients received
preoperative chemotherapy. Patients whose lymph
nodes were metastasized by the tumor received post-
operative irradiation treatment or systemic chemo-
therapy. Cancer tissues were obtained from each
patient immediately after esophagectomy, quickly
frozen in liquid nitrogen, and stored at –80°C until
analysis.
DNA preparation, bisulfite modification, and
methylation-specific polymerase chain reaction (PCR)
Genomic DNA samples from frozen esophageal
cancer tissue were isolated by the use of the GeneAll®
Tissue SV Plus (GeneAll Biotechnology, Seoul,
Korea), according to the manufacturer’s protocol.
One mg of DNA was digested with restriction enzyme
(Hind III, Intron Biotechnology, Sungnam, Korea)
and bisulfite modification was performed by use of
the CpGenome™ Fast DNA Modification Kit
(Chemicon, Temecula, CA, USA). Because treatment
of genomic DNA with sodium bisulfite converts unm-
ethylated cytosine to uracil whereas it does not
convert methylated cytosine, the DNA sequences
become different according to the methylation status.
PCR primers specific for either methylated or unm-
ethylated DNA sequences were designed. We
searched promoter methylation of p16 INK4a(p16),
RARbP2, adenomatosis polyposis coli (APC), FHIT,
hMLH1, and RASSF1A genes. Primer sequences of
p16 were 5′-GTT TGG AAA GAT ATC GCG GT-3′
(sense) and 5′-CCA CCA ACT CCA TAC TAC
TC-3′ (antisense) for the unmethylated reaction and
5′-TGG AAA GAT ATC GCG GTT TT-3′ (sense)
and 5′-CCG CCG ACT CCA TAC TAC TC-3′ (anti-
sense) for methylated reaction. The primer sequences
of RARb P2 for the unmethylated reaction were
5′-TTG AGA ATG TGA GTG ATT TGA-3′ (sense)
and 5′-AAC CAA TCC AAC CAA AAC AA-3′
(antisense), and for the methylated reaction, they
were 5′-TCG AGA ACG CGA GCG ATT CG-3′
(sense) and 5′-GAC CAA TCC AAC CGA AAC
GA-3′ (antisense). The primer sequences of APC
were 5′-GTG TTT TAT TGT GGA GTG TGG
GTT-3′ (sense) and 5′-CCA ATC AAC AAA CTC
CCA ACA A-3′ (antisense) for the unmethylated
reaction, and 5′-TAT TGC GGA GTG CGG
GTC-3′ (sense) and 5′-TCG ACG AAC TCC CGA
CGA-3′ (antisense) for the methylated reaction. The
primer sequences of FHIT for the unmethylated reac-
tion were 5′-TTG GGG TGT GGG TTT GGG TTT
TTA TG-3′ (sense) and 5′-CAT AAA CAA CAC
CAA CCC CAC TA-3′ (antisense), and for the
methylated reaction, the sequences were 5′-TTG
GGG CGC GGG TTT GGG TTT TTA CGC-3′
(sense) and 5′-CGT AAA CGA CGC CGA CCC
CAC TA-3′ (antisense). The primer sequences of
hMLH1 for the unmethylated reaction were 5′-GGT
TAT GGG TAA GTT GTT TTG-3′ (sense) and
5′-CCT AAT CTA TCA CCA CCT CAT C-3′ (anti-
sense), and for the methylated reaction, the sequences
were 5′-ACG GGT AAG TCG TTT TGA CG-3′
(sense) and 5′-TAA TCT ATC GCC GCC TCA
TC-3′ (antisense). The primer sequences of
RASSF1A for the unmethylated reaction were
5′-GGT TTT GTG AGA GTG TGT TTA-3′ (sense)
and 5′-CAC TAA CAA ACA CAA ACC AAA C-3′
(antisense); for the methylated reaction, they were
5′-GGG TTT TGC GAG AGC GCG-3′ (sense) and
5′-GCT AAC AAA CGC GAA CCG-3′ (antisense).
All PCR amplifications were performed using the
Eppendorf thermocycler (Mastercycler®, Eppendorf
Corp, Germany) with tube control for accurate
annealing temperatures. Every reaction was per-
formed with the hot-start method using the Qiagen
HotStart Master Mix Kit (Qiagen Corp, Valencia,
CA, USA). The PCR conditions of the four genes
were as follows: 95°C for 15 minutes, then 35 cycles of
94°C for 30 seconds, the specific annealing tempera-
ture for 45 seconds and 72°C for 1 minute, and a final
extension of 5 minutes at 72°C. The specific annealing
temperatures of the six genes were 62°C for the
methylated p16 gene, 53°C for the unmethylated p16
gene; 57°C for the methylated RARb P2 gene, 55°C
for the unmethylated RARb P2 gene; 64°C for the
methylated APC gene, 58°C for the unmethylated
APC gene; 66°C for the methylated FHIT gene, 62°C
for the unmethylated FHIT gene; 66°C for the methy-
lated hMLH1 gene, 55°C for the unmethylated
hMLH1 gene; and 64°C for the methylated
RASSF1A gene, 55°C for the unmethylated
RASSF1A gene. CpGenome™ Universal Methylated
DNA (Chemicon, Temecula, CA, USA) was used as
a positive control for methylated alleles of each gene.
Water control was added as a negative control. The
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PCR products were analyzed on a 2.5% agarose gel,
stained with ethidium bromide, and visualized by
ultraviolet illumination.
Immunohistochemical staining
We made a tissue microarray from paraffin blocks
of each specimen using a trephine apparatus (Super-
biochips Laboratories, Seoul, Korea). Immunohis-
tochemical staining was performed for APC
(Abcam, Cambridge, UK) using the Ultra LP
Detection kit from Labvision (Fremont, CA, USA),
for b-catenin (BD Transduction laboratories, Lex-
ington, KY, USA) using the Vector kit (Vector
laboratories, Burlingame, CA, USA), and for
E-cadherin (Novocastra, Newcastle, UK) using the
LSAB kit (DAKO, Carpinteria, CA, USA), accord-
ing to the manufacturer’s protocol. Briefly, sections
were deparaffinized, rehydrated, and then heated in
a microwave for 15 minutes within a citric acid
buffer (0.01 M, pH 6.0) for antigen retrieval. After
blocking endogenous peroxidase activity with 3%
hydrogen peroxide, slides were immersed in the
blocking solution, followed by incubation with the
primary antibody for 1 hour at room temperature.
For APC, primary antibody enhancer and horserad-
ish peroxidase polymer (Labvision Ultra LP Detec-
tion kit) were sequentially applied. For b-catenin,
biotinylated secondary antibody and avidin-
biotinylated peroxidase (Vector kit) were used, and
for E-cadherin, biotinylated secondary antibody and
peroxidase-labeled streptavidin were sequentially
applied. The sections were visualized using 3,3′-
diaminobenzidine and counterstained with Mayer’s
hematoxylin. For negative controls, normal rabbit
IgG was used instead of the primary antibody.
Immunohistochemical reactivity for APC was
classified into three groups, 0 (no reactivity), 1+
(weak reactivity), and 2+ (moderate to strong reactiv-
ity). For b-catenin, we followed the evaluation
method previously described.1 The intensity of mem-
branous staining of b-catenin was graded as 0 (nega-
tive, complete loss of membrane expression), 1+
(weak), 2+ (moderate) or 3+ (strong), and the propor-
tion of tumor cells showing membranous expression
was graded as 0 (<5% of tumor cells), 1 (5–25%), 2
(26–50%), 3 (51–75%), or 4 (>75%). A final score of
each sample was achieved by multiplying the intensity
and the proportion value; we then defined final scores
of 6–12 as preserved membranous expression, and
0–5 as reduced expression. Cytoplasmic expression of
b-catenin was classified as follows: 0, negative (no
cytoplasmic staining); 1+, <5% of tumor cells with
cytoplasmic staining; 2+, 5–25%; 3+, >25%. We
defined the score 0 and 1 as preserved cytoplasmic
staining and 2–3 as accumulated expression. Nuclear
staining for b-catenin was scored as follows: negative
(no nuclear staining), 1+ (1–5% of tumor cells with
nuclear staining), 2+ (5–10%), 3+ (>10%). With
respect to E-cadherin staining, if more than 50% of
tumor cells showed distinct membranous staining, the
tumor was defined as having preserved expression
(score 2+). If 5–50% of tumor cells showed membra-
nous staining, the tumor was deemed as reduced
expression (score 1+). Membranous staining in less
than 5% of tumor cells was considered as negative
(score 0).
Data collection and statistical analysis
We collected clinical variables including gender, age,
pathological TNM stage, number of positive lymph
nodes, development of recurrence, and survival.
Among the 50 patients, six patients underwent
incomplete resection (five microscopic and one gross
residual tumor) and two patients died early postop-
eratively. Excluding those eight patients, 42 patients
were followed regularly at the clinic. The medical
records were collected until the closing date of
August 31, 2007. The mean follow-up period was
35  21 months (range, 4–81 months). Careful
history taking, physical examinations, and chest
X-rays were performed every 3 months, and chest
computed tomography scans and esophageal
contrast studies were obtained on an annual basis.
If there were any symptoms or observations sug-
gesting recurrence, additional evaluations were
performed.
Statistical differences between groups were exam-
ined by the use of c2-test and Fisher’s exact test
with continuity corrections. As the distribution of
patients’ number in each category was not appropri-
ate for analysis, we merged it as follows: for the age,
older (60 years) and younger (<60 years); for the T
stage, early (T2) and late T stage (>T2); for the
immunohistochemical staining of APC, negative
(score 0) and positive (score 1+ and 2+); for immuno-
histochemical staining of E-cadherin, negative (score
0) and positive (score 1+ and 2+). Overall survival and
recurrence patterns were investigated by using the
Kaplan–Meier method, and the difference between
groups determined by risk factors were tested by
using the log–rank test. Cox regression analysis was
used to explore the influence of independent prognos-
tic factors in a multivariable model. The factors were
chosen by a stepwise forward method, with criteria
for variable inclusion and exclusion of 0.10. A 5%
significance level was considered for statistical
significance.
RESULTS
Promoter methylation and clinical features
Promoter CpG island hypermethylations were
observed in 10% (5/50) for p16, 34% (17/50) for
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RARbP2, 46% (23/50) for APC, 14% (7/50) for
RASSF1A, 84% (42/50) for FHIT, and 8% (4/50)
for hMLH1 from the cancer tissue.
Pathological TNM stages included stage I in eight
patients, IIA in 15 patients, stage IIB in four patients,
stage III in 22 patients, and stage IV in one patient.
The numbers of harvested lymph nodes were 34.8 per
patient (2–118). We analyzed for an association
between T or N stage and individual gene methyla-
tion. APC promoter hypermethylation was fre-
quently found in patients without lymph node
metastasis compared with those with lymph node
metastasis (62.5%; 15/24 vs 30.8%; 8/26, P = 0.025).
Other genes, however, did not show significant asso-
ciation with T or N stage (Table 1).
We analyzed the number of metastatic lymph
nodes according to the methylation status of the APC
gene. The number of metastatic lymph nodes was
lower in patients with APC promoter hypermethyla-
tion (0.87  0.30 vs 3.07  0.72 nodes, P = 0.008,
Figure 1).
Excluding patients of operative mortality and
those who underwent incomplete resections, 42
patients were analyzed for long-term outcome.
During the follow-up period, 17 patients (40.5%)
developed recurrence and 14 died. Additional 10
patients died without evidence of recurrence. Clinical
variables such as gender, age, TNM stages, and gene
methylation patterns were tested as to whether they
affect clinical outcomes. For survival analysis, none
of the methylation status of the six genes affected
survival. When we analyzed recurrence, unmethyla-
tion of APC (P = 0.0015) and FHIT (P = 0.0044), as
well as the presence of lymph node metastasis
(P = 0.0038), were risk factors in univariable analysis
(Figure 2). In the Cox regression model, we found
that lymph nodes metastasis (P = 0.050) and unm-
ethylation of APC promoter (P = 0.023) remained as
significant risk factors (Table 2).
APC promoter methylation and
immunohistochemical staining
To evaluate downstream proteins of the Wnt/b-
catenin signal pathway, we compared promoter
methylation of APC with the immunohistochemical
stain results of APC, b-catenin, and E-cadherin.
However, there was no correlation between APC pro-
moter hypermethylation and the APC immunohis-
tochemical stain (P = 0.539). We were not able to find
any significant correlation between APC methylation
and b-catenin protein expression either (Figure 3).
We then included the Wnt/b-catenin pathway mol-
ecules along with the clinical variables for the analysis
of recurrence. In univariable analysis, none of the
Table 1 Association between DNA methylation and clinicopathological features of esophageal squamous cell carcinoma
Feature
p16 RARbP2 APC FHIT hMLH1 RASSF1A
U M U M U M U M U M U M
Male 42 5 31 16 26 21 8 35 43 4 42 5
Female 3 0 2 1 1 2 0 3 3 0 1 2
P = 1.000 P = 1.000 P = 0.588 P = 1.000 P = 1.000 P = 0.048
Age 60 12 0 8 4 8 4 3 9 12 0 11 1
Age >60 33 5 25 13 19 19 5 33 34 4 32 6
P = 0.319 P = 1.000 P = 0.313 P = 0.379 P = 0.560 P = 1.000
T1, T2 14 1 11 4 8 7 4 11 13 2 12 3
T3, T4 31 4 22 13 19 16 4 31 33 2 31 4
P = 1.000 P = 0.474 P = 0.951 P = 0.220 P = 0.574 P = 0.415
N0 21 3 15 9 9 15 4 20 21 3 20 4
N1 24 2 18 8 18 8 4 22 25 1 23 3
P = 0.661 P = 0.616 P = 0.025 P = 1.000 P = 0.340 P = 0.697
U, unmethylated; M, methylated.
Fig. 1 Comparison of number of lymph nodes metastasized by
the tumor according to the adenomatosis polyposis coli (APC)
hypermethylation.
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immunohistochemical stain results showed signifi-
cance as a risk factor for recurrence. However, in the
Cox regression model, we found that lymph node
metastasis (P = 0.004), unmethylation of APC pro-
moter (P = 0.028), increased expression of APC
(P = 0.027), and decreased expression of E-cadherin
(P = 0.020) remained as significant risk factors for the
development of recurrence (Table 3).
DISCUSSION
In this study, we found that aberrant promoter
hypermethylation frequently occurs in esophageal
squamous cell carcinoma, as in other malignancies.
Among the six genes we tested, FHIT, APC, and
RARbP2 were more frequently hypermethylated
with prevalence of 84, 46, and 34%, respectively,
whereas that of p16, RASSF1A, and hMLH1 was
low. There are limited published reports concerning
DNA methylation of esophageal squamous cell car-
cinoma; hence, not enough information is available.
APC promoter methylation was reported as one of
the most frequent epigenetic alteration in esoph-
ageal adenocarcinoma ranging from 68 to 92% of
tumors.2,3 However, in esophageal squamous cell
carcinoma, the frequency of APC methylation was
reported to be as low as 50%.4 Our series, where a
larger number of samples had been used, showed
similar results of 46%. According to the literature,
the frequency of RARbP2 methylation in squamous
cell carcinoma of the esophagus varies from
25–55%,5,6 which is similar to our result of 34%. It is
of interest that the frequency of p16 methylation
was only 10% in our series, whereas others reported
as high as 64–80%.7,8 In a different paper, however,
it was reported as only 18%.9 For hMLH1, the fre-
quency of methylation is more controversial. The
reported frequency varies from as low as 20%9,10 to
as high as 62–67%.11,12 Our data showed only 8%.
The situation is similar for FHIT. The reported fre-
quency of methylation for FHIT varies from 14 to
70%.6,9,13–16 Our result demonstrated 84%, which is
the highest frequency reported. For RASSF1A, the
reported frequency varies from 24 to 51%6,17,18 and is
a little higher than our own data of 14%. We do not
have a clear explanation for such a large difference.
Possible explanations may be ethnic differences, dif-
ferent patient selection, or a different set of PCR
primer sequence used. These discrepancies could
also be attributed to an intrinsic problem of speci-
ficity related to PCR.
As the aberrant promoter hypermethylation of
tumor suppressor genes will result in decreased
expression of tumor suppressor protein, it is logical
to postulate that promoter methylation will offer a
Fig. 2 Probability of having recurrence in patients with resected
esophageal squamous cell carcinoma in relation to adenomatosis
polyposis coli (APC) promoter hypermethylation. A statistically
significant difference in recurrence rate was observed between
APC promoter methylation-positive and negative groups
(P = 0.0034).





Gender (male) 0.5993 – –
Age (60) 0.7904 – –
T stage (>2) 0.4739 – –
N stage (N1) 0.0038 3.196 (1.001–10.207) 0.050
p16 (methylated) 0.7039 – –
RARbP2 (methylated) 0.2089 – –
APC (methylated) 0.0015 0.226 (0.063–0.814) 0.023
FHIT (methylated) 0.0044 – –
hMLH1 (methylated) 0.2528 – –
RASSF1A (methylated) 0.3815 – –
APC, adenomatosis polyposis coli; HR, hazard ratio.
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poor prognosis. In esophageal adenocarcinoma, for
example, Brock and associates suggested that posi-
tive methylation status for multiple genes in esoph-
ageal adenocarcinoma was a predictor of poor
survival.2 However, in our reports, the aberrant pro-
moter hypermethyation of APC gene, which is a
well-known tumor suppressor gene, showed strong
correlation with improved outcome in terms of
recurrence. We also found that the APC promoter
hypermethylation was closely correlated with N
staging. When we further analyzed the number of
metastasized lymph nodes, APC hypermethyation
was related to a fewer number of metastasized
lymph nodes. Based on these observations, we pos-
tulated that the hypermethylation of APC may
influence a protective effect on the malignant cells
from being metastasized either into lymph nodes or
into the systemic circulation.
Invasion and metastases, the most life-
threatening properties of malignant tumors, consist
of sequential changes in host–tumor interaction.
The suppression of cell–cell adhesiveness may
trigger the release of cancer cells from the primary
cancer nests and confer invasive properties on a
tumor.19 Reduced cell–cell adhesiveness is thus con-
sidered indispensable for both the early and the late
carcinogenesis steps. In such cell–cell adhesion,
E-cadherin–catenin adhesion complex has been
considered as the prime mediators of calcium-
dependant cell–cell adhesion.20 More evidence is
now appearing to suggest that an inverse correlation
is found between the expression of the E-cadherin–
Fig. 3 Immunohistochemical staining of adenomatosis polyposis coli (APC) and b-catenin proteins. Note (a) a negative and (b) a
positive staining for APC; (d) a reduced and (e) a preserved staining of b-catenin on the cell membrane (¥200). There was no
correlation between APC promoter hypermethyaltion and expression of either (c) APC or (f)membranous b-catenin.






Gender (male) 0.5993 – –
Age (60) 0.7904 – –
T stage (>2) 0.4739 – –
N stage (N1) 0.0038 6.850 (1.843–25.463) 0.004
APC methylation (methylated) 0.0015 0.215 (0.055–0.846) 0.028
APC staining (positive) 0.3916 4.034 (1.174–13.859) 0.027
b-catenin staining (preserved) 0.6467 – –
E-cadherin staining (positive) 0.7431 0.047 (0.004–0.617) 0.020
APC, adenomatosis polyposis coli; HR, hazard ratio.
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catenin complex and the invasive behavior of tumor
cells.
To explain our result, we hypothesized that APC
methylation can perform as a protector of malig-
nant cell metastasis by affecting the E-cadherin–
catenin cell–cell adhesion complex through the Wnt/
b-catenin pathway. It is well known that APC acts
as a scaffold to promote phosphorylation, ubiquiti-
nation, and degredation of b-catenin, thus regulat-
ing the level of free b-catenin in the cell. For
example, mutation of APC results in truncated APC
protein, which can still complex with, but not
degrade, b-catenin.21 The result of APC mutation is
therefore an increase in cellular free b-catenin,
which will hold cells together by binding to
E-cadherins, both at the adherens junctions and the
actin cytoskeleton.22 On the other hand, the
increased level of cellular free b-catenin may enter
the nucleus and directly bind to the transcription
factors Lef and Tcf, leading to the activation of
gene expression, which subsequently triggers a
cascade of tumor formation.23–25 Besides point muta-
tion or deletion, aberrant hypermethylation was
found to act as one of the mechanisms of APC gene
inactivation in colorectal cancer.26 Our postulation
is that when APC promoter hypermethylation
occurs, APC protein will decrease, and subse-
quently, the level of cellular free b-catenin will
increase. The increased level of b-catenin will result
in increased E-cadherin–catenin complex, which
confers a protective effect of tumor cells from
metastasis. There is additional literature that sup-
ports our hypothesis. By isolating and analyzing
highly invasive clones in oral cancer cells, Kudo and
colleagues demonstrated that invasion and meta-
stasis of oral squamous cell cancer cells require
methylation of E-cadherin and/or degradation
of membranous b-catenin.27 So far, none of the
literature has reported a correlation between APC
methylation and lymph node metastasis in either
esophageal cancer or other type of cancers.
It is noteworthy that the finding of aberrant pro-
moter hypermethylation of any gene demands
further investigation but does not imply functional
significance until the promoter methylation can be
associated with the loss of expression. To prove our
hypothesis, we investigated downstream proteins of
Wnt/b-catenin pathway by performing immunohis-
tochemical staining for APC, b-catenin, and
E-cadherin. Unfortunately, however, we could not
clearly demonstrate a statistically significant corre-
lation between APC methylation status and its
downstream protein, APC and b-catenin. Although
we failed to associate APC methylation with loss of
protein expression, we believe it can be attributed to
using clinical samples that are heterogenous in the
aspect of molecular events. Because DNA methyla-
tion is not a single mechanism for gene silencing in
carcinogenesis, the research using clinical samples
can be frequently subjected to bias. For example, in
our previous reports of methylation study for lung
cancer, the promoter hypermethylation did not
always coincide with decreased expression of down-
stream proteins.28,29 Even though there was no sig-
nificance in univariable analysis, we were able to
demonstrate the expression levels of APC and
E-cadherin as well as methylation status of APC
promoter, which were related to the recurrence in
multivariable analysis. It is indeed interesting
because the odd ratios of each factor coincide well
with our hypothesis (Table 3).
Our observation suggested that APC promoter
hypermethylation might affect the metastasis of
esophageal squamous cell carcinoma by means of
the Wnt/b-catenin signal pathway. Because we had
not calculated an appropriate sample size at the
time of study design, the power of testing of Cox
proportional hazard model may not be limited. To
further convince our result, we performed post-hoc
testing for APC methylation using PASS statistical
package (NCSS, Kaysville UT, USA). The power of
post-hoc testing for APC methylation was 0.77243
in Table 2, and 0.74929 in Table 3. These high
values of post-hoc testing power suggested that the
alternative hypothesis, “APC methylation affects
recurrence,” could be supported in high probability.
However, because the sample size of our study was
small and had not been determined prospectively,
and because the follow-up period was relatively
short, our study has a limitation for generalization.
Accordingly, future investigations are mandatory to
clarify the mechanism of APC gene methylation for
preventing lymph node metastasis. To achieve such
a goal, future endeavors, such as larger series studies
including far advanced stage patients and testing
metastasized lymph nodes, are necessary. For more
concrete evidence, we need in vitro studies where one
can demonstrate the reversal of downregulation of
APC protein and increase of cellular b-catenin
when hypermethylated APC is reactivated by
demethylation.
Although we were not able to demonstrate a
clear mechanism, we demonstrated that APC pro-
moter hypermethylation was associated with fewer
occurrences of lymph node metastasis and, as a
consequence, resulted in better clinical outcome in
respect to recurrence-free status. Our observation
may be used to identify high-risk patients who may
possess occult lymph node metastasis, and subse-
quently be used to identify patients who need more
aggressive lymph node dissection or who can receive
benefits from postoperative adjuvant systemic che-
motherapy. Additionally, our results suggested that
the development of a new therapeutic modality tar-
geting on the Wnt/b-catenin pathway may be prom-
ising in the prevention of cancer cell metastasis.
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